S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
From -60% Account to Doubling His Money? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
From -60% Account to Doubling His Money? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
From -60% Account to Doubling His Money? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
From -60% Account to Doubling His Money? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
ETR:MDG1

Medigene (MDG1) Stock Forecast, Price & News

€1.60
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
€1.59
▼
€1.64
50-Day Range
€1.55
▼
€1.91
52-Week Range
€1.50
▼
€2.80
Volume
2,488 shs
Average Volume
306,207 shs
Market Capitalization
$39.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlines

MDG1 stock logo

About Medigene (ETR:MDG1) Stock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

June 1, 2023 | finance.yahoo.com
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
May 30, 2023 | finance.yahoo.com
Medigene AG to participate at BIO International in Boston
June 7, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 22, 2023 | technews.tmcnet.com
Medigene AG Expands Patent Portfolio for its End-to-End Platform
May 22, 2023 | finance.yahoo.com
Medigene AG Expands Patent Portfolio for its End-to-End Platform
May 12, 2023 | msn.com
Medigene (FWB:MDG1) Price Target Decreased by 39.29% to 8.67
May 8, 2023 | finance.yahoo.com
Medigene AG to present at upcoming investor conferences
May 4, 2023 | finance.yahoo.com
Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment
June 7, 2023 | Behind the Markets (Ad)
"The $51 Billion Laser Revolution"
See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>
May 3, 2023 | finance.yahoo.com
Medigene AG reports financial results and business update for Q1 2023
April 27, 2023 | finance.yahoo.com
Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
April 24, 2023 | finance.yahoo.com
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
April 18, 2023 | finance.yahoo.com
New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)
April 18, 2023 | finance.yahoo.com
New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)
April 4, 2023 | finance.yahoo.com
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
April 3, 2023 | finance.yahoo.com
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
April 1, 2023 | finance.yahoo.com
Medigene Full Year 2022 Earnings: €0.34 loss per share (vs €0.41 loss in FY 2021)
March 29, 2023 | finance.yahoo.com
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
March 20, 2023 | finance.yahoo.com
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
March 16, 2023 | finance.yahoo.com
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
March 15, 2023 | finance.yahoo.com
Medigene AG to report full year 2022 financial results on March 29, 2023
March 10, 2023 | benzinga.com
Medigene Amends 2022 Financial Guidance
March 10, 2023 | finance.yahoo.com
Medigene Amends 2022 Financial Guidance
February 23, 2023 | finance.yahoo.com
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
February 22, 2023 | finance.yahoo.com
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 15, 2023 | finance.yahoo.com
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
February 15, 2023 | finance.yahoo.com
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
See More Headlines

MDG1 Price History

Industry, Sector and Symbol

Stock Exchange
ETR
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ETR:MDG1
CUSIP
N/A
CIK
N/A
Web
www.medigene.de
Phone
+49-89-2000330
Fax
N/A
Employees
58
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
(€0.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
7.12
Net Income
$-8,330,000.00
Net Margins
-26.66%
Pretax Margin
N/A
Return on Equity
-20.36%
Return on Assets
13.14%

Debt

Debt-to-Equity Ratio
10.06
Current Ratio
5.02
Quick Ratio
5.85

Sales & Book Value

Annual Sales
$31.25 million
Price / Sales
1.25
Cash Flow
€1.17 per share
Price / Cash Flow
1.37
Book Value
€1.51 per share
Price / Book
1.06

Miscellaneous

Outstanding Shares
24,560,000
Free Float
N/A
Market Cap
$39.17 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Dr. Dolores J. Schendel
    Chief Scientific Officer, Member of Exec. Management Board and Head of R&D
  • Dr. Selwyn Ho MB BS (Age 51)
    MBBS, CEO & Member of Exec. Management Board
  • Dr. Ernst-Ludwig Winnacker (Age 81)
    Co-Founder & Chairman Scientific Advisory Board
  • Dr. Birger Kohlert
    Chief Financial Officer
  • Dr. Rene Goedkoop
    Acting Chief Medical Officer

Key Competitors

View All Competitors













MDG1 Stock - Frequently Asked Questions

How have MDG1 shares performed in 2023?

Medigene's stock was trading at €2.02 at the beginning of the year. Since then, MDG1 shares have decreased by 21.0% and is now trading at €1.60.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Medigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).

What is Medigene's stock symbol?

Medigene trades on the ETR under the ticker symbol "MDG1."

What is Medigene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €1.60.

How much money does Medigene make?

Medigene (ETR:MDG1) has a market capitalization of $39.17 million and generates $31.25 million in revenue each year. The company earns $-8,330,000.00 in net income (profit) each year or (€0.34) on an earnings per share basis.

How can I contact Medigene?

Medigene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The official website for the company is www.medigene.de. The company can be reached via phone at +49-89-2000330.

This page (ETR:MDG1) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -